Partnerships

The most impactful molecular technologies are built through collaboration. Renew partners with innovators, providing the sequencing, assay development, bioinformatics, and clinical laboratory expertise needed to move from discovery to clinical impact.

Turn Promising Biology Into Deployable Assays

Native-read and long-read sequencing can reveal biology that standard methods miss. Renew helps translate those insights into deployable assays through integrated development, validation, and clinical laboratory capabilities.

“Renew helped us translate promising epigenetic biology into a clinically deployable test by bringing together assay development, validation, bioinformatics, and clinical laboratory execution. That integrated support was instrumental in moving NOA Guide from scientific concept to a test that can provide patients and clinicians with greater clarity at an important point in the fertility journey.”

Kristin Brogaard, PhD · Co-founder & CSO · Path Fertility

Generate Datasets That Power Better Models

Better models start with better data. Renew works with AI and biopharma teams to generate high-quality multiomic datasets for biomarker discovery, translational research, and model development.

“Renew has been instrumental in helping us generate high-quality, multiomic datasets. Their integrated sequencing, laboratory, and bioinformatics capabilities have given us greater confidence in the biological signals within our data and allowed us to progress our models to the next stage of development.”

Dominik Klein · CTO · Valinor

Bringing Clinical Products To The Markets They Serve

Renew develops sequencing technologies and products to support better clinical decisions. Their impact depends on reaching the providers and patients they were built to serve.

Through strategic partnerships, Renew helps move new technologies from development into adoption, bringing advanced molecular insights into clinical care.

“Our collaboration with Renew Biotechnologies represents an exciting opportunity to bring a new type of testing to our physician network. We look forward to expanding the tools available to providers and supporting the continued evolution of personalized patient care.”

Jennifer Gillen · Director, Marketing · Boston Heart Diagnostics

Advance The Native-Read Sequencing Ecosystem

Short-read sequencing defined the last era of genomics. The next will be built on richer molecular insight.

Renew partners with technology developers to advance sequencing platforms and workflows that accelerate long-read and native-read adoption across research and clinical applications.

“Partnering with Renew gives our customers more flexibility in how they access advanced sequencing. By combining SureSelect enrichment with Renew’s sequencing technology and send-out service, customers can generate high-quality sequencing data without having to bring a new workflow in-house.”

Nina Green · VP Clinical Diagnostics · Agilent Technologies

The Renew Advantage

Renew partnerships are structured to advance programs from early feasibility through development, validation, launch, and long-term support within a unified operating model.

From the outset, we integrate sequencing strategy, laboratory execution, specialty bioinformatics, custom LIMS, API-enabled data access, and clinical laboratory operations to support seamless development and scalable deployment.